Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma

Cancer

Volumn 118, Issue 6, 2012, Pages 1566-1573

  Lin, Pei ^a   Dickason, Timothy J ^a   Fayad, Luis E ^a   Lennon, Patrick A ^a   Hu, Peter ^a   Garcia, Mar ^a   Routbort, Mark J ^a   Miranda, Roberto ^a   Wang, Xumei ^a   Qiao, Wei ^a   Medeiros, L Jeffrey ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Burkitt lymphoma; diffuse large B cell lymphoma; gray zone lymphoma; high grade B cell lymphoma; MYC

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; KI 67 ANTIGEN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MYC PROTEIN; PREDNISOLONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CELL STRUCTURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX SCORE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; ONCOGENE BCL2; ONCOGENE MYC; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SCORING SYSTEM; STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; FEMALE; GENE REARRANGEMENT; GENES, MYC; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 84863230289     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26433     Document Type: Article

References (23)

1. Carbone A, Gloghini A, Aiello A, et al. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol. 2010; 41: 621-631.
2. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006; 354: 2419-2430. (Pubitemid 43855045)
3. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006; 354: 2431-2442. (Pubitemid 43855046)
4. Kluin PM, Harris NL, Stein H, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In:, Swerdlow S, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008: 265-266.
5. Boerma EG, Siebert R, Kluin PM, et al. Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. Leukemia. 2009; 23: 225-234.
6. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106: 1569-1580.
7. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987-994.
8. Barakat FH, Medeiros LJ, Wei EX, et al. Residual monotypic plasma cells in patients with Waldenstrom macroglobulinemia. Am J Clin Pathol. 2011; 135: 365-373.
9. Yin CC, Lin P, Carney DA, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. Am J Clin Pathol. 2005; 123: 594-602. (Pubitemid 40418555)
10. Lin P, Chen L, Luthra R, et al. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic alterations. Mod Pathol. 2008; 21: 1029-1035.
11. Dang CV, O'Donnell KA, Zeller KI, et al. The c-Myc target gene network. Semin Cancer Biol. 2006; 16: 253-264. (Pubitemid 44311039)
12. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009; 114: 3533-3537.
13. Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia. 2008; 22: 2226-2229.
14. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010; 28: 3360-3365.
15. Obermann EC, Csato M, Dirnhofer S, et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol. 2009; 62: 754-756.
16. Niitsu N, Okamoto M, Miura I, et al. Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci. 2009; 100: 233-237.
17. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011; 117: 2319-2331.
18. Kanungo A, Medeiros LJ, Abruzzo LV, et al. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006; 19: 25-33. (Pubitemid 43250976)
19. Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 1999; 17: 1558-1567.
20. Le Gouill S, Talmant P, Touzeau C, et al. Diffuse large B-cell lymphoma (DLBCL) with t(14;18) and 8q24/c-MYC rearrangement is a lymphoid neoplasm with aggressive clinical presentation and very poor prognosis. Hematologica. 2007; 92: 1335-1342. (Pubitemid 350144150)
21. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009; 114: 2273-2279.
22. Lin P, Medeiros LJ,. High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. Haematologica. 2007; 92: 1297-1301. (Pubitemid 350144145)
23. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009; 94: 935-943.